Trends in Prescription Drug Launch Prices, 2008-2021

Prescription drug spending in the US exceeded half a trillion dollars in 2020. Spending is driven by high-cost brand-name drugs, for which manufacturers freely set prices after approval. Rising brand-name drug prices often translate to payers restricting access, raising premiums, or imposing unaffordable out-of-pocket costs for patients. We evaluated recent trends in prices for newly marketed brand-name drugs.

Methods | We identified drugs newly marketed from 2008 to 2021 within SSR Health, a database with quarterly whole-sale acquisition cost (ie, list prices) and estimated net prices after manufacturer discounts for more than 1230 brand-name products. For drugs with multiple dosage forms, we included the first marketed version. Price per unit was converted to price per year (or course of treatment, if <1 year) based on US Food and Drug Administration (FDA)-approved labeling; in cases of weight-based dosing, US population averages were used. Prices were converted to 2021 dollars using the Consumer Price Index for All Urban Consumers.

We used linear regression to estimate trends in mean launch prices, which were log transformed to improve normality and fit observed exponential trends. We adjusted for drug characteristics, including biologics vs small molecules, novel active ingredients vs reformulations, accelerated vs traditional FDA approval, Orphan Drug Act designation for rare conditions vs nonrare conditions, oncology vs nononcology indications, and oral vs injected vs other route of administration. In a secondary analysis, we included interaction terms between each characteristic and time to determine if trends varied between subgroups (2-tailed; P < .05). In another secondary analysis, we used estimated net prices after manufacturer discounts among non-Medicaid payers, if such estimates were available from SSR Health within 1 year after launch. Analyses were performed using SAS version 9.4 (SAS Institute Inc).

Results | We included 548 of 576 drugs (95%) first marketed in 2008-2021, excluding 3 diagnostics and 25 drugs for which we could not estimate price per year (eg, as-needed use). Overall, 357 (65%) were new molecules, 139 (25%) were biologics, 182 (33%) treated rare diseases, 64 (12%) received accelerated approval, 119 (22%) were oncologic agents, and 282 (51%) were orally administered (Table). The highest prices were among drugs for rare diseases (median, $168 441 [IQR, $78 291-$338 379] per year) and oncology drugs (median, $155 091 [IQR, $109 832-$233 916] per year).

Median launch prices increased from $2115 per year (IQR, $928-$17 866) per year in 2008 to $180 007 (IQR, $20 236-409 732) per year in 2021 (Figure). The proportion of drugs priced at $150 000 per year or more was 9% (18/197) in 2008-2013 and 47% (42/89) in 2020-2021. Unadjusted mean launch prices increased exponentially by 20.4% per year (95% CI, 15.3%-25.8% per year). Adjusting for drug characteristics, mean prices increased exponentially by 13.0% per year (95% CI, 9.4%-16.7% per year). Most drug characteristics were independently associated with launch price, and including interaction terms revealed that launch prices increased more quickly among biologics, drugs treating rare diseases, and nononcology drugs (Table).

Estimated net prices were available for 395 drugs (72%); these net prices were a median of 14% lower than the wholesale acquisition cost in 2008 and 24% lower in 2020. Net prices increased from a median of $1376 (IQR, $693-$10 897) in 2008 to $159 042 (IQR, $31 187-$380 509) in 2021. Adjusting for drug characteristics, mean net prices increased exponentially by 10.7% per year (95% CI, 6.3%-15.2% per year).

Discussion | From 2008 to 2021, launch prices for new drugs increased exponentially by 20% per year. In 2020-2021, 47% of new drugs were initially priced above $150 000 per year. Prices increased by 11% per year even after adjusting for estimated manufacturer discounts and changes in certain drug characteristics, such as more oncology and specialty drugs (eg, injectables, biologics) introduced in recent years. The study was
Figure. Prices for Newly Marketed Drugs, 2008-2021

Each box-and-whisker plot represents the price per year (in 2021 US dollars) of drugs first marketed each year, from 2008 to 2021. Boxes indicate 25th to 75th percentiles; horizontal lines, medians; white squares, means. Outliers are shown except for 6 drugs with launch prices exceeding $1 million per year: sebelipase alfa (Kanuma, 2015; $1.2 million per year), inotuzumab ozogamicin (Besponsa, 2018; $1.0 million per year), tagraxofusp-erzs (Elzonris, 2019; $2.2 million per year), onasemnogene abeparvovec (Zolgensma, 2019; $2.2 million per year), naxitamab-gqgk (Danyelza, 2021; $3.2 million per year), and asparaginase erwinia chrysanthemi-rywn (Rylaze, 2021; $1.6 million per year). Date of market entry was determined primarily based on the first year a price was listed in SSR Health. However, if the first listed price in SSR Health occurred 1 year or more after US Food and Drug Administration approval, an industry database (IBM Red Book) was used to verify and correct, if necessary, the date of market entry and launch price.

Table. Differences in Prices and Price Trends for Newly Marketed Drugs From 2008-2021, by Drug Characteristics

<table>
<thead>
<tr>
<th>Drug characteristicsa</th>
<th>Drugs, No. (%)</th>
<th>Price per y, 2008-2021, median (IQR), $</th>
<th>Adjusted relative differences in mean priceb</th>
<th>Adjusted absolute difference in % price increase per yc</th>
<th>Estimate (95% CI)</th>
<th>P value</th>
<th>Estimate (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All drugs</td>
<td>548</td>
<td>20 657 (3929-138 509)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novelty</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New active ingredient</td>
<td>357 (65)</td>
<td>68 596 (7276-184 065)</td>
<td>1.7 (1.2-2.2)</td>
<td>0.4 (-6.9 to 8.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reformulationd</td>
<td>191 (35)</td>
<td>5429 (2105-18 782)</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
<td>.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ingredient type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologic</td>
<td>139 (25)</td>
<td>84 508 (18 861-288 759)</td>
<td>2.2 (1.5-3.4)</td>
<td>13.7 (2.9 to 25.7)</td>
<td></td>
<td>.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small molecule</td>
<td>409 (75)</td>
<td>10 580 (3076-38 916)</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
<td>.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Approval pathway</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accelerated approvala</td>
<td>64 (12)</td>
<td>168 344 (115 609-240 302)</td>
<td>0.9 (0.6-1.5)</td>
<td>–0.4 (-11.2 to 11.6)</td>
<td></td>
<td>.94</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traditional approval</td>
<td>484 (88)</td>
<td>12 912 (3434-96 030)</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
<td>.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient population</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rared</td>
<td>182 (33)</td>
<td>168 441 (78 291-338 179)</td>
<td>6.8 (5.0-9.2)</td>
<td>8.1 (0.5 to 16.4)</td>
<td></td>
<td>.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonrare</td>
<td>366 (67)</td>
<td>6252 (2675-33 227)</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
<td>.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>119 (22)</td>
<td>155 091 (109 832-233 916)</td>
<td>3.7 (2.5-5.3)</td>
<td>-10.3 (-18.3 to -1.5)</td>
<td></td>
<td>.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nononcology</td>
<td>429 (78)</td>
<td>7783 (2963-52 483)</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Route of administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td>282 (51)</td>
<td>15 630 (3948-115 609)</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injected</td>
<td>199 (36)</td>
<td>72 875 (9908-236 164)</td>
<td>0.9 (0.6-1.4)</td>
<td>-6.0 (-14.3 to 3.0)</td>
<td></td>
<td>.19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Otherd</td>
<td>67 (12)</td>
<td>3545 (1542-6689)</td>
<td>0.4 (0.3-0.6)</td>
<td>-0.5 (-10.4 to 10.4)</td>
<td></td>
<td>.92</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a Drug characteristics were obtained from Drugs@FDA, linked to SSR Health data based on brand name.

b Estimates are from a linear regression model of log-transformed price; the model included year of market entry (rounded to calendar quarter) plus all listed characteristics as independent variables. The results shown are exponentiated coefficients and reflect the relative difference in mean price, adjusting for all other characteristics and time. For example, mean prices for oncology drugs were 3.7 times higher than those for nononcology drugs.

c Estimates are from a second linear regression model that additionally included interaction terms between year of market entry and each characteristic. The results shown are based on exponentiated coefficients and reflect the difference in the annual percent increase in price. For example, mean prices for oncology drugs increased by 10.3% per year less than those for nononcology drugs.

d Reformulations included any product for which the US Food and Drug Administration had previously approved a different product with the same active ingredient. This included new formulations of existing drugs (eg, long-acting depot injections), new manufacturers, and new combination products.

e The US Food and Drug Administration accelerated approval program allows approval of drugs that treat a serious condition or fill an unmet need to be approved based on evidence of efficacy using a surrogate end point that is only reasonably likely to predict a clinical end point.

f Under the Orphan Drug Act, a drug is intended to treat a rare condition that affects fewer than 200 000 individuals in the US.

g Includes 18 inhaled, 18 transdermal, 9 ophthalmic, 7 nasal, 5 vaginal, 4 implanted, 4 sublingual, 1 instilled, and 1 rectal.
limited to drugs sold by public companies; SSR Health net price estimates have limitations, including underestimating net prices paid by payers.3,4

The trend in prices for new drugs outpaces growth in prices for other health care services.5 Even after drugs are marketed, manufacturers routinely increase prices over time; in another analysis, net prices increased by 4.5% per year from 2007 to 2018.3 In response to the current trends, the US could stop allowing drug manufacturers to freely set prices and follow the example of other industrialized countries that negotiate drug prices at launch.6

Benjamin N. Rome, MD, MPH
Alexander C. Egilman, BA
Aaron S. Kesselheim, MD, JD, MPH

Author Affiliations: Program on Regulation, Therapeutics, and Law (PORTAL), Brigham and Women’s Hospital, Boston, Massachusetts.

Accepted for Publication: March 24, 2022.

Correction: This article was corrected on June 7, 2022, to update data in the Table as a result of a reanalysis. The adjusted numbers do not affect the primary outcome.

Corresponding Author: Benjamin N. Rome, MD, MPH, Brigham and Women’s Hospital, Program on Regulation, Therapeutics, and Law (PORTAL), 1620 Tremont St, Ste 3030, Boston, MA 02120 (brone@bwh.harvard.edu).

Author Contributions: Dr Rome had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Rome, Kesselheim.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Rome.

Critical revision of the manuscript for important intellectual content: Egilman, Kesselheim.

Statistical analysis: Rome.

Obtained funding: Kesselheim.

Supervision: Kesselheim.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was funded by a grant from Arnold Ventures.

Role of the Funder/Sponsor: Arnold Ventures had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.


COMMENT & RESPONSE

Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave

To the Editor: The recently published Research Letter1 about the clinical characteristics of hospitalized patients with COVID-19 during the fourth wave found that these patients, who were predominantly infected with the Omicron variant (80%-90% according to the NextStrain database3), were younger, less likely to have comorbidities, and less likely to have acute respiratory conditions compared with patients during the previous waves of COVID-19. While this observation appears reassuring, I have several questions.

In the first 3 waves, COVID-19 vaccinations were either not approved or not widely available in South Africa; however, in the fourth wave, 24.2% of patients in this cohort1 were vaccinated.

Given new evidence showing that individuals who received 3 doses of the BNT162b2 vaccine (Pfizer-BioNTech) generated reduced levels of neutralization against the Omicron strain compared with the wild type or the Delta variant,4 it is important to perform a subgroup analysis comparing demographic characteristics and disease severity between vaccinated and unvaccinated patients in this study. Further analysis could demonstrate real-world messenger RNA COVID-19 vaccine effectiveness during the Omicron wave.

Furthermore, it would be informative to compare the outcomes of the unvaccinated hospitalized patients during the Omicron wave with unvaccinated individuals from prior waves in order to understand the intrinsic virulence of the Omicron variant. Moreover, as the authors pointed out, from the second wave onward, every hospitalized patient underwent rapid SARS-CoV-2 antigen screening on admission, and therefore asymptomatic or mildly symptomatic patients could have been included. A subgroup analysis focusing on symptomatic COVID-19 patients would help elucidate the disease trajectory of symptomatic hospitalized patients infected with the Omicron variant. This information may be useful if health care systems in some countries start to experience surges in hospitalization and limited hospital bed capacity again.5

Yijia Li, MD

Author Affiliation: Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts.

Corresponding Author: Yijia Li, MD, Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215 (yli48@partners.org).

Conflict of Interest Disclosures: None reported.


Yijia Li, MD